ArticleBreast cancer research and treatment2013
Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients.
Article in Breast cancer research and treatment, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed.
- Metabolic consequences of perioperative oral carbohydrates in breast cancer patients - an explorative study.BMC cancer · 2019Trial
- CDK4/6 inhibitor combined with endocrine therapy: a real-world evaluation of efficacy and safety in HR+/HER2- advanced breast cancer.World journal of surgical oncology · 2026Article
- Article
- The Hematological Variations and Effect of Cadmium Induced Toxicity on Mammary Tumors Development in Albino Mice. A Comparative Model Study on the Effect of Heavy Metals in Human Breast Cancer.Anti-cancer agents in medicinal chemistry · 2026Article
- Multifunctional magnetic nanocapsules for dual delivery of siRNA and chemotherapy to MCF-7 cells (Breast cancer cells).Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Breast cancer incidence and mortality, by age, stage and molecular subtypes, by race/ethnicity in Canada.The oncologist · 2025Article
- Article
- Predicting estrogen receptor status from HE-stained breast cancer slides using artificial intelligence.Frontiers in medicine · 2025Article
- The value of intratumoral and peritumoral radiomics features based on multiparametric MRI for predicting molecular staging of breast cancer.Frontiers in oncology · 2025Article
- Improvement in breast cancer survival across molecular subtypes in Hungary between 2011 and 2020: a nationwide, retrospective study.Frontiers in oncology · 2025Article
- Construction of a novel mitochondrial oxidative stress-related genes prognostic system and molecular subtype characterization for breast cancer.Discover oncology · 2024Article
- Microsphere-Enabled Modular Formation of Miniaturized In Vitro Breast Cancer Models.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Exploration of the relationship between tumor-infiltrating lymphocyte score and histological grade in breast cancer.BMC cancer · 2024Article
- Article
- Involvement of FAM170B-AS1, hsa-miR-1202, and hsa-miR-146a-5p in breast cancer.Cancer biomarkers : section A of Disease markers · 2024Article
- Discovery of a new marker to identify myeloid cells associated with metastatic breast tumours.Cancer cell international · 2023Article
- Evaluation of the association of area-level socioeconomic deprivation and breast cancer recurrence by oestrogen receptor subtypes in Scotland.Breast cancer research : BCR · 2023Article
- Oestrogen receptor low positive breast cancer: associations with prognosis.Breast cancer research and treatment · 2023Article
- Dynamic contrast-enhanced magnetic resonance imaging radiomics analysis based on intratumoral subregions for predicting luminal and nonluminal breast cancer.Quantitative imaging in medicine and surgery · 2023Article
- Neoadjuvant chemotherapy response, disease-free survival, and overall survival of breast cancer in a single institution.Surgery open science · 2023Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular subtyping of breast cancer may provide additional prognostic information regarding patient outcome. However, its clinical significance remains to be established. In this study, the main aims were to discover whether reclassification of breast cancer into molecular subtypes provides more precise information regarding outcome compared to conventional histopathological grading and to study breast cancer-specific survival in the different molecular subtypes. Cases of breast cancer occurring in a cohort of women born between 1886 and 1928 with long-term follow-up were included in the study. Tissue microarrays were constructed from archival formalin-fixed, paraffin-embedded tissue from 909 cases. Using immunohistochemistry and in situ hybridisation as surrogates for gene expression analyses, all cases were reclassified into the following molecular subtypes: Luminal A; Luminal B (HER2-); Luminal B (HER2+); HER2 subtype; Basal phenotype; and five negative phenotype. Kaplan-Meier survival curves and Cox proportional hazards models were used in the analyses. During the first 5 years after diagnosis, there were significant differences in prognosis according to molecular subtypes with the best survival for the Luminal A subtype and the worst for HER2 and five negative phenotype. In this historic cohort of women with breast cancer, differences in breast cancer-specific survival according to subtype occur almost exclusively amongst the histopathological grade 2 tumours. From 5 years after time of diagnosis until the end of follow-up, there appears to be no difference in survival according to molecular subtype or histopathological grade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.